What to know
- Seasonal flu activity continues to increase nationally.
- Note: Due to the Thanksgiving Holiday, FluView for Week 46 will be posted on November 30, 2026.
Summary
All data are preliminary and may change as more reports are received.
A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the surveillance methods page. Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
Key Points
- Multiple seasonal influenza surveillance indicators continue to increase nationally.
- Many surveillance indicators are higher than typically observed at this time of year, but an earlier increase in activity does not necessarily lead to a higher seasonal peak or greater severity overall.
- During Week 45 (the week ending November 14, 2026), of the 613 influenza viruses reported by public health laboratories, 608 were influenza A and 5 were influenza B. Of the 365 influenza A viruses subtyped, 352 (96.4%) were influenza A(H1N1)pdm09, 12 (3.3%) were A(H3N2), and 1 (0.3%) was A(H5).
- Since Week 21 (the week ending May 30, 2026), 84.8% of the influenza A viruses reported have been A(H1N1)pdm09 and among these, the majority have been HA subclade E (newly designated alias of D.3.1.1).
- The influenza A(H1N1) viruses detected this season are still A(H1N1)pdm09 viruses, which emerged in 2009 and have circulated globally since. Influenza viruses are constantly changing, often requiring updates to influenza vaccines every season.
- Historically, influenza A(H1N1)pdm09 viruses have changed less often than A(H3N2) viruses. This week, recently circulating influenza A(H1N1)pdm09 viruses which were previously designated D.3.1.1 HA subclade have been reclassified into subclade E (with newly designated HA subclades E.1 to E.4), each with different combinations of genetic changes in their HA genes.
- It is too early to know what viruses may predominate or to say whether there might be implications on flu vaccine effectiveness this season. So far, almost all the influenza viruses collected and antigenically characterized in the U.S. since Week 21 are antigenically similar to their respective influenza vaccine reference viruses based on CDC laboratory assays.
- Two pediatric deaths associated with season influenza virus infection occurring during the 2026-2027 influenza season were reported to CDC this week for a total of seven deaths this season.
- Because case investigation takes time, flu-associated deaths in children may be reported to CDC weeks after they occur; counts are preliminary and may increase. All reported cases meet the influenza-associated pediatric mortality case definition.
- The preliminary in-season severity assessment has classified the severity of influenza activity at this point in the season as low across all ages and all age groups. The severity assessment for the season changes with flu activity.
- CDC estimates that there have been at least 3,700,000 illnesses, 50,000 hospitalizations, and 2,800 deaths associated with flu so far this season.
- CDC’s FluSight forecasts predict a likely increase nationally in both flu hospital admissions and the percentage of emergency department visits due to flu for the week ending November 28. The number of new flu hospital admissions is forecast to range from 9,200 to 36,100 admissions, while the national percentage of emergency department visits due to flu is forecast to range from 1.7% to 7.6%.
- Annual seasonal flu vaccination is recommended. Influenza vaccines are available for persons aged 6 months and older. People who are recommended for influenza vaccination but have not been vaccinated yet this season are encouraged to be vaccinated now. Influenza vaccination coverage estimates and influenza vaccine doses distributed for this season are available in FluVaxView.
- There are prescription flu antiviral drugs that can treat flu illness; those should be started as early as possible and are especially important for patients at higher risk for influenza complications.1
- One confirmed human case of avian influenza A(H5) virus infection was reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.
- Influenza viruses are among several viruses contributing to respiratory disease activity. CDC is providing updated, integrated information about COVID-19, flu, and respiratory syncytial virus (RSV) activity on a weekly basis.
U.S. Virologic Surveillance
Nationally, and in HHS regions 1, 3, and 8, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories remained stable (change of less than 0.5 percentage points) compared to the previous week. The percentage of positive specimens increased in regions 4, 5, 6, and 7 and decreased in regions 2, 9, and 10 (change of greater than 0.5 percentage points). Decreases in regions 9 and 10 could be due to incomplete reporting. A(H1N1)pdm09 viruses were the most frequently reported influenza viruses by public health laboratories this week and this season. For regional and state level data and age group distribution, please visit FluView Interactive. Viruses known to be associated with recent receipt of live attenuated influenza vaccine (LAIV) or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
Clinical Laboratories
The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza virus) are used to monitor whether influenza activity is increasing or decreasing.
| Week 45 | Data Cumulative since October 4, 2026 (Week 40) |
|
|---|---|---|
| No. of specimens tested | 61,838 | 395,732 |
| No. of positive specimens (%) | 7,269 (11.8%) | 35,011 (8.8%) |
| Positive specimens by type | ||
| Influenza A | 7,209 (99.2%) | 34,533 (98.6%) |
| Influenza B | 60 (0.8%) | 478 (1.4%) |
Public Health Laboratories
The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating influenza viruses that belong to each influenza subtype.
| Week 45 | Data Cumulative since October 4, 2026 (Week 40) |
|
|---|---|---|
| No. of specimens tested | 1,240 | 12,236 |
| No. of positive specimens | 613 | 6,548 |
| Positive specimens by type/subtype | ||
| Influenza A | 608 (99.2%) | 6,452 (98.5%) |
| Subtyping performed | 365 (60.0%) | 5,688 (88.2%) |
| (H1N1)pdm09 | 352 (96.4%) | 5,594 (98.3%) |
| H3N2 | 12 (3.3%) | 89 (1.6%) |
| H3N2v† | 0 | 0 |
| H5* | 1 (0.3%) | 5 (0.1%) |
| Subtyping not performed | 243 (40.0%) | 764 (11.8%) |
| Influenza B | 5 (0.8%) | 96 (1.5%) |
†When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a "variant" influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but person-to-person transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.
*These data reflect specimens tested, and the number determined to be positive for influenza viruses at the public health labs (specimens tested are not the same as human cases of A(H5) virus infection). If a specimen is only tested at CDC, it is not reflected in these data. The data could include more than one specimen tested per person. For more information on the number of people infected with A(H5) viruses, please visit the "How CDC is monitoring influenza data among people to better understand the current avian influenza A (H5N1) situation"
This graph reflects the number of specimens determined to be positive for influenza viruses at the public health laboratory (specimens tested are not the same as cases). It does not reflect specimens tested only at CDC and could include more than one specimen tested per person. Specimens tested as part of routine influenza surveillance as well as those tested as part of targeted testing for people exposed to influenza A(H5) are included.
Novel Influenza A Virus Infections
One confirmed human infection with influenza A(H5) virus was reported to CDC this week. To date, human-to-human transmission of influenza A(H5) virus has not been identified in the United States.
The case was reported by the Oregon Health Authority and occurred in a worker aged ≥18 years at a commercial dairy cattle farm where highly pathogenic avian influenza (HPAI) A(H5) virus has been detected in cows. This individual developed eye irritation during the week ending November 15, 2026 (Week 45), which they reported to the local health department. Specimens were collected from the individual and tested at the state public health laboratory where a conjunctival specimen tested presumptive positive for influenza A(H5) virus using the CDC influenza A(H5) assay. Influenza A(H5) virus was confirmed at CDC. This is the first influenza A(H5) case associated with a dairy worker in Oregon.
There has been a total of four influenza A(H5) cases in dairy workers reported in 2026.
Notification to WHO of this case was completed per International Health Regulations (IHR). More information regarding IHR can be found at http://www.who.int/topics/international_health_regulations/en/.
The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/position_statements_files_2023/24-ID-09_Novel_Influenza_A.pdf.
An up-to-date human case summary during the 2024 outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.
Information about avian influenza is available at https://www.cdc.gov/bird-flu/.
Interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevention/hpai-interim-recommendations.html.
The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.
Influenza Virus Characterization
CDC performs genetic and antigenic characterization of U.S. viruses submitted from state and local public health laboratories according to the Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating influenza viruses are relative to the reference viruses representing the current influenza vaccines. The data are also used to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. CDC also tests susceptibility of circulating influenza viruses to antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the polymerase acidic protein (PA) endonuclease inhibitor baloxavir. The HA clade and subclades were assigned using Nextclade (https://clades.nextstrain.org) and are helpful in tracking which viruses are circulating and changing in proportion. New subclade designations may be introduced to split larger groups and improve tracking of emerging viruses and shifts in their relative proportions. The naming system often renames longer subclades with a single letter as is the case with the influenza A(H1N1)pdm09 subclade E which is a newly designated alias of D.3.1.1.
CDC has genetically characterized 835 influenza viruses collected since May 24, 2026
| Virus Subtype or Lineage |
Genetic Characterization | ||||
|---|---|---|---|---|---|
| Total No. of Subtype/ Lineage Characterized |
HA Clade | Number (% of subtype/ lineage Characterized) |
HA Subclade | Number (% of subtype/lineage Characterized) | |
| A(H1N1)pdm09 | 617 | ||||
| 5a.2a.1 | 617 (100%) | D.3.1 | 1 (0.2%) | ||
| E (alias of D.3.1.1) | 137 (22.2%) | ||||
| E.1 | 287 (46.5%) | ||||
| E.2 | 2 (0.3%) | ||||
| E.3 | 171 (27.7%) | ||||
| E.4 | 19 (3.1%) | ||||
| A(H3N2) | 117 | ||||
| 2a.3a.1 | 117 (100%) | J.2.4.2 | 5 (4.3%) | ||
| K | 103 (88.0%) | ||||
| K.1 | 3 (2.6%) | ||||
| K.2 | 1 (0.9%) | ||||
| K.3 | 5 (4.3%) | ||||
| B/Victoria | 101 | ||||
| 3a.2 | 101 (100%) | C.3.1 | 40 (39.6%) | ||
| C.3.3 | 1 (1.0%) | ||||
| C.5.1 | 3 (3.0%) | ||||
| C.5.6 | 8 (7.9%) | ||||
| C.5.6.1 | 49 (48.5%) | ||||
Genetic Characterization of Hemagglutinin Genes from Influenza Viruses Collected since May 24, 2026
CDC antigenically characterizes influenza viruses by hemagglutination inhibition (HI) assay (H1N1pdm09, H3N2, and B/Victoria viruses) or neutralization-based HINT (H3N2 viruses) using antisera that ferrets make after being infected with reference viruses representing the 2026-2027 Northern Hemisphere recommended cell-, recombinant- and nucleic acid-based vaccine viruses. Antigenic differences between viruses are determined by comparing how well the antibodies made against the vaccine reference viruses recognize the circulating viruses that have been grown in cell culture. Ferret antisera are useful because antibodies raised against a particular virus can often recognize small changes in the surface proteins of other viruses. In HI assays, viruses with similar antigenic properties have antibody titer differences of less than or equal to 4-fold when compared to the reference (vaccine) virus. In HINT, viruses with similar antigenic properties have antibody neutralization titer differences of less than 8-fold. Viruses selected for antigenic characterization are a subset of the recent genetically characterized viruses and are chosen based on the genetic changes in their surface proteins and may not be proportional to the number of such viruses circulating in the United States.
Influenza A Viruses
- A(H1N1)pdm09: 182 A(H1N1)pdm09 viruses were antigenically characterized by HI, and 170 (93.4%) were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown A/Missouri/11/2025-like reference viruses representing the A(H1N1)pdm09 component for the cell-, recombinant- and nucleic acid-based influenza vaccines.
- A(H3N2): 38 A(H3N2) viruses were antigenically characterized by HI or HINT, and all were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer in HI or reacting at titers that were less than 8-fold of the homologous virus in HINT) by ferret antisera to cell-grown A/Darwin/1415/2025-like reference viruses representing the A(H3N2) component for the cell-, recombinant- and nucleic acid-based influenza vaccines.
Influenza B Viruses
- B/Victoria: 38 influenza B/Victoria-lineage viruses were antigenically characterized by HI, and all were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown B/Pennsylvania/14/2025-like reference viruses representing the B/Victoria component for the cell-, recombinant- and nucleic acid-based influenza vaccines.
Assessment of Virus Susceptibility to Antiviral Medications
CDC assesses susceptibility of influenza viruses to the antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir using next generation sequence analysis supplemented by laboratory assays. Information about antiviral susceptibility test methods can be found at U.S. Influenza Surveillance: Purpose and Methods | CDC.
Viruses collected in the U.S. since May 24, 2026, were tested for antiviral susceptibility as follows:
| Antiviral Medication | Total Viruses | A/H1 | A/H3 | B/Victoria |
|---|---|---|---|---|
| Neuraminidase Inhibitors | ||||
| Oseltamivir | ||||
| Viruses Tested | 781 | 571 | 112 | 98 |
| Reduced Inhibition | 8 (1.0%) | 8 (1.4%) | 0 | 0 |
| Highly Reduced Inhibition | 0 | 0 | 0 | 0 |
| Peramivir | ||||
| Viruses Tested | 781 | 571 | 112 | 98 |
| Reduced Inhibition | 0 | 0 | 0 | 0 |
| Highly Reduced Inhibition | 0 | 0 | 0 | 0 |
| Zanamivir | ||||
| Viruses Tested | 781 | 571 | 112 | 98 |
| Reduced Inhibition | 0 | 0 | 0 | 0 |
| Highly Reduced Inhibition | 0 | 0 | 0 | 0 |
| PA Cap-Dependent Endonuclease Inhibitor | ||||
| Baloxavir | ||||
| Viruses Tested | 755 | 539 | 113 | 103 |
| Decreased Susceptibility | 0 | 0 | 0 | 0 |
Eight A(H1N1)pdm09 viruses had amino acid substitutions NA-I223V and NA-S247N and showed reduced inhibition by oseltamivir.
High levels of resistance to the adamantanes (amantadine and rimantadine) persist among influenza A(H1N1)pdm09 and influenza A(H3N2) viruses (the adamantanes are not effective against influenza B viruses). Therefore, use of these antivirals for treatment and prevention of influenza A virus infection is not recommended and data from adamantane resistance testing are not presented.
Outpatient and Emergency Department Illness Surveillance
ILINet
The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient and emergency department visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and can therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms. It is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete picture.
Nationally, during Week 45, 3.8% of patient visits reported through ILINet were due to ILI. This week's national percentage increased (change of > 0.1 percentage points) compared to Week 44 and is above the national baseline of 2.9% for the second consecutive week. ILI activity remained stable (change of ≤ 0.1 percentage points) in region 1, and increased in all other HHS regions (2, 3, 4, 5, 6, 7, 8, 9, and 10) compared to Week 44. Regions 1, 2, 4, 6, 8, 9, and 10 are above their respective baselines, while regions 3, 5, and 7 are below their respective baselines. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.
*Some calendar years do not include an epidemiologic Week 53. In those years, the Week 53 value shown is the average between Week 52 and Week 1.
**Effective October 3, 2021 (Week 40), the respiratory illness definition (fever plus cough or sore throat) no longer includes "without a known cause other than influenza."
The percentage of visits for respiratory illness increased (change of > 0.1 percentage points) in all age groups (0-4 years, 5-24 years, 25-49 years, 50-64 years and 65 years and older) this week compared to the previous week.
ILI Activity Map
Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
| Activity Level | Number of Jurisdictions | Number of CBSAs | ||
|---|---|---|---|---|
| Week 45 (Week ending Nov. 14, 2026) |
Week 44 (Week ending Nov. 7, 2026) |
Week 45 (Week ending Nov. 14, 2026) |
Week 44 (Week ending Nov. 7, 2026) |
|
| Very High | 2 | 1 | 11 | 8 |
| High | 9 | 7 | 57 | 38 |
| Moderate | 13 | 9 | 104 | 66 |
| Low | 14 | 15 | 174 | 180 |
| Minimal | 17 | 23 | 377 | 431 |
| Insufficient Data | 0 | 0 | 206 | 206 |
*Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of respiratory virus activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.
National Syndromic Surveillance System (NSSP)
The national percentage of emergency department (ED) visits with a discharge diagnosis (DD) of influenza reported in NSSP was 2.4% during Week 45 and increased (change of > 0.1 percentage point) compared to the previous week. Nationally, the percentage of ED visits with a DD of influenza increased among the 0-4 years and 5-17 years age groups and remained stable (change of ≤ 0.1 percentage point) among the 18-64 years and 65 years and older age groups. The percentage of ED visits with a DD of influenza increased in regions 4, 6, 8, 9, and 10, and remained stable in all other HHS regions (1, 2, 3, 5, and 7) this week compared to the previous week.
Hospitalization Surveillance
FluSurv-NET
The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 10% of the U.S. population. FluSurv-NET hospitalization data are preliminary. As data are received each week, prior case counts and rates are updated accordingly.
A total of 4,497 laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between October 4, 2026, and November 14, 2026. The weekly hospitalization rate observed during Week 45 was 2.3 per 100,000 population. After accounting for reporting delays, the estimated rate during Week 45 likely ranges from 2.8 to 3.7. Estimated weekly rates continue to increase. The cumulative hospitalization rate observed in Week 45 was 12.0 per 100,000 population, which is the highest cumulative rate observed for Week 45 since the 2010-11 season.
Among all hospitalizations, 4,410 (98.1%) were associated with influenza A virus, 78 (1.7%) with influenza B virus, 1 (<0.1%) with influenza A virus and influenza B virus co-infection, and 8 (0.2%) with influenza virus for which the type was not determined. Among those with influenza A subtype information, 7 (0.8%) were A(H3N2), and 926 (99.2%) were A(H1N1)pdm09.
When examining rates by age, the highest rate of hospitalization per 100,000 population was among adults aged 65 and older (38.1), followed by adults aged 50-64 years (12.8), children aged 0-4 years (11.8), children aged 5-17 years (4.2), and adults aged 18-49 years (3.9).
When examining age-adjusted rates by race and ethnicity, the highest rate of hospitalization per 100,000 population was among non-Hispanic Black persons (21.1), followed by Asian and/or Pacific Islander persons (13.3), Hispanic persons (11.7), American Indian or Alaska Native persons (10.9), and non-Hispanic White persons (9.4).
National Healthcare Safety Network (NHSN) Hospital Respiratory Data
Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 45, 11,734 laboratory-confirmed, influenza-associated hospitalizations were reported. This week's influenza-associated hospital admission rate (3.5 per 100,000 population) increased (difference of ≥ 0.25) compared to Week 44.
Laboratory-confirmed influenza-associated hospital admission rates per 100,000 population increased in regions 3, 4, 6, 7, 8, 9 and 10 and remained stable in regions 1, 2, and 5. Regional admission rates during Week 45 ranged from 1.1 (Region 7) to 4.5 (Region 4).
When examining rates by age for Week 45, the 0-4 years, 50-64 years, 65 years and older age groups increased (difference of ≥ 0.25) and the 5-17 years and 18-49 years age groups remained stable (difference of < 0.25) compared to the previous week. The highest hospital admission rate per 100,000 population was among those 65 years and older (10.6), followed by the 0-4 years age group (4.0), and the 50-64 years age group (3.4).
Mortality Surveillance
National Center for Health Statistics (NCHS)
Based on NCHS mortality surveillance data available on November 19, 2026, 0.6% of the deaths that occurred during the week ending November 14, 2026 (Week 45) were due to influenza. This percentage increased (≥ 0.1 percentage point change) compared to Week 44. The data presented are preliminary and may change as more data are received and processed.
Influenza-Associated Pediatric Mortality
Three influenza-associated pediatric deaths were reported to CDC during Week 45.
Two deaths occurred during the 2026-2027 season, bringing the total pediatric deaths for this season to seven. The deaths occurred during Week 44 (the week ending November 7, 2026) and Week 45 (the week ending November 14, 2026). Both deaths were associated with influenza A(H1N1) viruses.
One death occurring during the 2025-2026 season was also reported, which brings the total number of pediatric deaths for last season to 204. This death was associated with an influenza B/Victoria lineage virus and occurred during Week 14 of 2026 (the week ending April 11, 2026).
For surveillance purposes, an influenza-associated pediatric death is defined as a death in a person less than 18 years of age, resulting from a clinically compatible illness that was confirmed to be influenza by an appropriate laboratory diagnostic test. There should be no period of complete recovery between the illness and death.
The data presented are preliminary and may increase as additional cases are identified and reported to CDC.
Additional National and International Influenza Surveillance Information
FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.
U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information.
Public Health Agency of Canada:
The most up-to-date influenza information from Canada is available in Canada's weekly FluWatch report.
Public Health England:
The most up-to-date influenza information from the United Kingdom is available from Public Health England.
Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.
A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.
This page was last updated on this date. Updates may include minor edits, image changes, or other modifications to page content.
The information on this page was last reviewed by subject matter experts to ensure accuracy.